Summit Therapeutics Share Discussion Threads

[kirk 6] 09/7/2019 22:14

Nice close on nasdaq let's hope this goes back above 32p

[chrisatrdg] 09/7/2019 21:57

Interesting development today:

Development of new antibiotics encouraged with new pharmaceutical payment system:

The NHS will test the world's first ‘subscription’ style payment model to incentivise pharmaceutical companies to develop new drugs for resistant infections.

[waterloo01] 09/7/2019 16:20

kirk6, volume is all on Nasdaq these days so that will drive the share price (remember ADR's are 5:1)

[bermudashorts] 09/7/2019 16:09

goosed - excellent!

[kirk 6] 09/7/2019 16:03

Why no price movement again ? All this good news ?

[cascudi] 09/7/2019 16:00

Strange to not see a big movement. Probably spread is too high?

[waterloo01] 09/7/2019 15:56

kirk6, THIS you can call a game changer.

[waterloo01] 09/7/2019 15:45

Excellent. Great find and important news.

The new trial will be led by the National Institute for Health and Care Excellence (NICE) and NHS England and NHS Improvement.

It will test a ‘subscription’ style model that pays pharmaceutical companies upfront for access to drugs based on their usefulness to the NHS.

This will make it more attractive for companies to invest the estimated £1 billion it costs to develop a new drug, as they can be reassured they will still be paid for the drug even though it may be stored for reserves.


------------
Today we are sending a strong signal to the rest of the world that there are workable models to stimulate investment in these vital medicines and that together we can tackle AMR.

[waterloo01] 09/7/2019 13:05

Very encouraging and builds the proposition as a focused and 'exquisite' antibiotic play. As and when the market decides to value antibiotics, it should make SUMM a particularly tasty morsel.

[algernon2] 09/7/2019 12:50

Let's not gild the lilly too much Kirk,but certainly another small layer of gilt leaf if not yet a complete "game changer"

[kirk 6] 09/7/2019 12:41

Game changing news surely?

[smarner] 09/7/2019 12:28

Good news day?

[algernon2] 09/7/2019 12:28

Good news.

"Summit Therapeutics plc Summit's Dds-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy In Sepsis And Pneumoni"


See RNS:

[waterloo01] 07/7/2019 09:51

Thanks for the clarification. Much appreciated.

[bermudashorts] 07/7/2019 09:40

Waterloo,

Thanks for links, Summit's SMT-571 for gonorrhoea has huge potential and am looking forward to watching how it develops.

Regarding your Ridinilazole link - the EMA insist that every application for marketing approval for an adult drug is also accompanied by results from clinical studies carried out in children. A Paediatric Investigation Plan (PIP)details exactly how those studies will be carried out. I think the rationale behind it is that drug developers simply weren't bothering to develop drugs for children once they had received approval for the adult version, presumably in most cases it simply isn't commercially viable to do so.

Obviously there are drugs which will never be appropriate for children in which case the EMA will waive the need for a PIP. Companies can also apply to defer the implementation of the PIP and that is the case here. The link you have posted is to a decision from the EMA granting Summit's application to defer development of Ridinilazole in children as well as agreement of the PIP. This means that they'll be able to submit for marketing approval when the time comes without the need for study data on children.

[waterloo01] 07/7/2019 09:14

Not sure posted before but Ridinilazole allowed by EMEA to use on children in phase 3 study from birth to 18 (published 24/06/19)

[waterloo01] 07/7/2019 07:57

"This is leading to untreatable infections like “super-gonorrhoea” which can even withstand drugs held back as a last resort.

Gut bacteria ensure that antiviral genes in the lung lining stay active and are ready to react as a first line of defence when flu emerges, the researchers found.

The cells lining the lung "are the only place that the virus can multiply, so they are the key battleground in the fight against flu,” they reported in the journal, Cell Reports.

They added: “Gut bacteria send a signal that keeps the cells lining the lung prepared, preventing the virus from multiplying so quickly.”

"We found that antibiotics can wipe out early flu resistance, adding further evidence that they should not be taken or prescribed lightly,​” says the study’s lead researcher, Dr Andreas Wack. “Inappropriate use not only promotes antibiotic resistance and kills helpful gut bacteria, but may also leave us more vulnerable to viruses.”

[kirk 6] 30/6/2019 18:10

Let's hope it's loosened up some of the selling from the placing. We know following the last 9m received this is along way from a dead duck and potential here is astronomical in my opinion!

[waterloo01] 30/6/2019 15:07

275k shares sold at 22.75 and then after hours a buy of 275k shares at 23.75. Not that I understand these things but a roll-over?

[waterloo01] 28/6/2019 16:26

and now down 10%. Go figure. Big sale on AIM of 275k of shares?

[kirk 6] 28/6/2019 15:46

Already over doubled average within first hour

[waterloo01] 28/6/2019 15:35

Yup. Last time it was just before the Barda announcement. Another leak or just a fund buying in?

[kirk 6] 28/6/2019 15:22

Sudden large spike in volume ?

[chrisatrdg] 26/6/2019 13:25

The reports from the last event are now on the website:

ASM Hub Track: Pharma Pipeline
June 2019
From New Mechanisms to New Standards of Care




SUNDAY - AAR-758
Sunday 23rd June 2019 ASM Microbe San Francisco
In-Vitro Activity of SMT-571 & Comparators Against Clinical Isolates & Reference Strains of Neisseria gonorrhoeae